Hospital-acquired Disease Testing Market Size and Growth, Current Analysis with Top Key Players Luminex Corporation, Diatherix Laboratories, Life Technologies, Cantel Medical Corporation

Hospital acquired disease or nosocomial infection is a localized or systemic condition in patients which occurs due to adverse reaction caused by infectious toxin agents during medical care, and were absent at the time of admission. Hospital-acquired infections result in prolonged hospital stay, antimicrobial resistance, long-term disabilities, and higher mortality rate. Pathogens responsible for hospital-acquired diseases include viruses, fungal parasites, and bacteria.

Hospital-acquired diseases also include catheter-related blood stream infections, surgical site infections, ventilator-associated pneumonia, and catheter-associated urinary tract infection. The technique used for prevention, diagnosis, and testing of hospital-acquired diseases are microarray, PCR, and solid phase hybridization. Urinary tract infections are most common in patients using urinary catheters as the urethra is located close to the anus, which increases the chances of bacterial invasion from the large intestine into the urinary tract.

Free Sample Report + All Related Graphs & Charts : https://www.coherentmarketinsights.com/insight/request-sample/992

The global hospital-acquired disease testing market is expected to be valued at US$ 925.4 million in 2019, and is expected to exhibit a CAGR of 20.0% over the forecast period (2019-2027).

Rising incidence of infections such as central line associated bloodstream infection (CLABSI), catheter-related bloodstream infection (CRBSI), and others are expected to drive growth of the hospital-acquired disease testing market over the forecast period. For instance, according to data published during the National Healthcare Safety Network Bloodstream Infection Surveillance in March 2018, around 30,000 CLABSI cases are reported every year in the U.S. CLABSI can prolong the hospital stay, which can increase the cost burden on patients and also lead to mortality.

Furthermore, according to the statistics published by the International Society for Infectious Diseases in March 2018, around 250,000 cases of blood stream infections are reported every year in the U.S. Among these, around 80,000 are catheter-related bloodstream infections (CRBSI) which occur in intensive care units.

Increasing launches of advanced and efficient testing tools and kits are expected to fuel the growth of the hospital-acquired disease testing market

Manufacturers are focusing on development of advanced testing kits to enhance the efficiency of hospital-acquired disease diagnosis. For instance, in December 2019, F.Hoffmann-La Roche Ltd. received the U.S. Food and Drug Administration (FDA) approval for cobas vivoDx MRSA, a diagnostic test designed to detect the Methicillin-resistant Staphylococcus aureus (MRSA) bacteria. The approval of cobas vivoDx MRSA is intended to aid in the control and prevention of the Methicillin-resistant Staphylococcus aureus (MRSA) infections in healthcare settings.

For Early Buyers | Get Up to 20-50% Discount on This Premium Report: https://www.coherentmarketinsights.com/insight/request-discount/992

However, decreasing prevalence of nosocomial infections due to the availability of advanced hospital-acquired disease tests in developed countries is likely to hinder the market growth in near future.

Key Players

Major players operating in the global hospital-acquired disease testing market include Luminex Corporation, Diatherix Laboratories, Life Technologies, Cantel Medical Corporation, Meridian Biosciences Inc, Nordion Inc, Qiagen GmbH, F.Hoffmann-La Roche Ltd., Biomérieux, and Cepheid.

Coherent Market Insights 1001 4th Ave,
#3200 Seattle, WA 98154,U.S.
Phone: US +1-206-701-6702/UK +44-020 8133 4027
Email: sales@coherentmarketinsights.com

About us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide.

This release was published on openPR.